Patents by Inventor David GROEGER

David GROEGER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION PRODUCT FOR PROPHYLAXIS AND TREATMENT OF IRRITABLE BOWEL SYNDROME
    Publication number: 20230405061
    Abstract: A combination product comprising an isolated strain of Bifidobacterium NCIMB 41003 and another strain which does not adversely interact with Bifidobacterium NCIMB 41003 improves gastrointestinal symptoms associated with IBS and improves one or more of mood, stress, anxiety, sleep quality and depression associated with IBS.
    Type: Application
    Filed: July 14, 2023
    Publication date: December 21, 2023
    Applicant: PRECISIONBIOTICS GROUP LIMITED
    Inventors: Barry KIELY, Eileen Frances MURPHY, David GROEGER
  • BIFIDOBACTERIUM LONGUM ABLE TO BENEFICIALLY MODULATE IMMUNE RESPONSE TO RESPIRATORY VIRUS INFECTION
    Publication number: 20230210921
    Abstract: Bifidobacterium longum strains and cell wall fractions isolated from Bifidobacterium longum strains are useful in the prophylaxis or treatment of a respiratory viral infection in a subject. They are also useful in the prophylaxis of a secondary bacterial infection associated with a respiratory viral infection in a subject, especially a subject who is susceptible to respiratory infections.
    Type: Application
    Filed: December 6, 2022
    Publication date: July 6, 2023
    Applicant: PrecisionBiotics Group Limited
    Inventors: Barry KIELY, Liam O'MAHONY, David GROEGER
  • BIFIDOBACTERIUM LONGUM
    Publication number: 20230106819
    Abstract: Bifidobacterium longum strains and cell wall fractions isolated from Bifidobacterium longum strains are useful in the prophylaxis or treatment of an infection in a subject caused by a coronavirus such as SARS-CoV-2. They are also useful in the prophylaxis of a secondary bacterial infection associated with an infection in a subject caused by a coronavirus, especially a subject who is susceptible to respiratory infections.
    Type: Application
    Filed: March 12, 2021
    Publication date: April 6, 2023
    Inventors: David GROEGER, Barry KIELY
  • Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
    Patent number: 11590179
    Abstract: Bifidobacterium longum strains and cell wall fractions isolated from Bifidobacterium longum strains are useful in the prophylaxis or treatment of a respiratory viral infection in a subject. They are also useful in the prophylaxis of a secondary bacterial infection associated with a respiratory viral infection in a subject, especially a subject who is susceptible to respiratory infections.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: February 28, 2023
    Assignee: PrecisionBiotics Group Limited
    Inventors: Barry Kiely, Liam O'Mahony, David Groeger
  • Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
    Patent number: 11529381
    Abstract: An isolated strain of Bifidobacterium longum NCIMB 42020 is useful for the treatment of viral infections, especially viral respiratory infections such as influenza, rhinovirus and RSV. Bifidobacterium longum NCIMB 42020 is also useful for clearing secondary bacterial infections.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: December 20, 2022
    Assignee: PrecisionBiotics Group Limited
    Inventors: Barry Kiely, Liam O'Mahony, David Groeger
  • COMBINATION PRODUCT FOR PROPHYLAXIS AND TREATMENT OF IRRITABLE BOWEL SYNDROME
    Publication number: 20220387523
    Abstract: A combination product comprising an isolated strain of Bifidobacterium NCIMB 41003 and another strain which does not adversely interact with Bifidobacterium NCIMB 41003 improves gastrointestinal symptoms associated with IBS and improves one or more of mood, stress, anxiety, sleep quality and depression associated with LBS.
    Type: Application
    Filed: June 17, 2022
    Publication date: December 8, 2022
    Applicant: PRECISIONBIOTICS GROUP LIMITED
    Inventors: Barry KIELY, Eileen Frances Murphy, David Groeger
  • Combination product for prophylaxis and treatment of irritable bowel syndrome
    Patent number: 11400123
    Abstract: A combination product comprising an isolated strain of Bifidobacterium NCIMB 41003 and another strain which does not adversely interact with Bifidobacterium NCIMB 41003 improves gastrointestinal symptoms associated with IBS and improves one or more of mood, stress, anxiety, sleep quality and depression associated with IBS.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: August 2, 2022
    Assignee: PrecisionBiotics Group Limited
    Inventors: Barry Kiely, Eileen Frances Murphy, David Groeger
  • BIFIDOBACTERIUM LONGUM NCIMB 41676
    Publication number: 20210127695
    Abstract: Bifidobacterium longum strain NCIMB 41676 improves sleep.
    Type: Application
    Filed: September 4, 2020
    Publication date: May 6, 2021
    Applicants: PrecisionBiotics Group Limited, University College Cork - National University of Ireland, Cork
    Inventors: Eileen Frances MURPHY, David GROEGER, Timothy DINAN, John CRYAN
  • NCIMB 41676
    Patent number: 10813366
    Abstract: Methods of treating a subject by administering Bifidobacterium longum strain NCIMB 41676 are discussed. The method may include orally administering a formulation comprising Bifidobacterium longum strain NCIMB 41676 to improve sleep.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: October 27, 2020
    Assignees: PrecisionBiotics Group Limited, University College Cork—National University of Ireland, Cork
    Inventors: Eileen Frances Murphy, David Groeger, Timothy Dinan, John Cryan
  • COMBINATION PRODUCT FOR PROPHYLAXIS AND TREATMENT OF IRRITABLE BOWEL SYNDROME
    Publication number: 20200289586
    Abstract: A combination product comprising a strain of Bifidobacterium NCIMB 41676 and a strain of Bifidobacterium NCIMB 41003 is used in the prophylaxis or treatment of irritable bowel syndrome (IBS). The combination product leads to a surprising, sustained positive effects, even after feeding has stopped.
    Type: Application
    Filed: January 29, 2019
    Publication date: September 17, 2020
    Inventors: Barry KIELY, Eileen Frances MUEPHY, David GROEGER
  • A COMBINATION PRODUCT FOR PROPHYLAXIS AND TREATMENT OF IRRITABLE BOWEL SYNDROME
    Publication number: 20200289587
    Abstract: A combination product comprising an isolated strain of Bifidobacterium NCIMB 41003 and another strain which does not adversely interact with Bifidobacterium NCIMB 41003 improves gastrointestinal symptoms associated with IBS and improves one or more of mood, stress, anxiety, sleep quality and depression associated with IBS.
    Type: Application
    Filed: January 29, 2019
    Publication date: September 17, 2020
    Inventors: Barry KIELY, Eileen Frances MURPHY, David GROEGER
  • BIFIDOBACTERIUM LONGUM NCIMB 41676
    Publication number: 20200214308
    Abstract: Bifidobacterium longum strain NCIMB 41676 improves sleep.
    Type: Application
    Filed: February 18, 2020
    Publication date: July 9, 2020
    Inventors: Eileen Frances MURPHY, David Groeger, Timothy Dinan, John Cryan
  • BIFIDOBACTERIUM LONGUM ABLE TO BENEFICIALLY MODULATE IMMUNE RESPONSE TO RESPIRATORY VIRUS INFECTION
    Publication number: 20200016220
    Abstract: Bifidobacterium longum strains and cell wall fractions isolated from Bifidobacterium longum strains are useful in the prophylaxis or treatment of a respiratory viral infection in a subject. They are also useful in the prophylaxis of a secondary bacterial infection associated with a respiratory viral infection in a subject, especially a subject who is susceptible to respiratory infections.
    Type: Application
    Filed: February 28, 2018
    Publication date: January 16, 2020
    Applicant: Alimentary Health Limited
    Inventors: Barry KIELY, Liam O'MAHONY, David GROEGER, Raymond Alan GRANT, David MICHALOVICH, Edith M. HESSEL, Richard A. WILLIAMSON
  • BIFIDOBACTERIUM LONGUM ABLE TO BENEFICIALLY MODULATE IMMUNE RESPONSE TO RESPIRATORY VIRUS INFECTION
    Publication number: 20200000859
    Abstract: An isolated strain of Bifidobacterium longum NCIMB 42020 is useful for the treatment of viral infections, especially viral respiratory infections such as influenza, rhinovirus and RSV. Bifidobacterium longum NCIMB 42020 is also useful for clearing secondary bacterial infections.
    Type: Application
    Filed: February 28, 2018
    Publication date: January 2, 2020
    Applicant: Alimentary Health Limited
    Inventors: Barry KIELY, Liam O'MAHONY, David GROEGER